Macleods FDA Wednesday, July 8, 2026 +0.20 Positive

FDA Approves DAPSONE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited (Macleods) has received FDA approval for the ANDA for DAPSONE, ensuring continued access to this essential medication for treating leprosy. The approval is critical for expanding availability amidst fluctuations in the global supply chain, reinforcing Macleods’ position as a stable supplier for this critical antiparasitic agent.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed